Andrea Lobo,  —

Andrea Lobo is a Science writer at BioNews. She holds a Biology degree and a PhD in Cell Biology/Neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. She was a postdoctoral and senior researcher at the Institute for Research and Innovation in Health in Porto, in drug addiction, studying neuronal plasticity induced by amphetamines. As a research scientist for 19 years, Andrea participated in academic projects in multiple research fields, from stroke, gene regulation, cancer, and rare diseases. She authored multiple research papers in peer-reviewed journals. She shifted towards a career in science writing and communication in 2022.

Articles by Andrea Lobo

Zambon gains exclusive rights to oral therapy IPX203 in Europe

Zambon Biotech has entered into an exclusive deal with Amneal Pharmaceuticals for rights to seek approval and commercialize the oral treatment IPX203 for Parkinson’s disease in the European Union, U.K., and Switzerland. IPX203 is an experimental extended-release formulation of carbidopa and levodopa, designed to ease…

Metabolite of cancer medication shows promise for Parkinson’s

A metabolite called M324 of the cancer medicine rucaparib is able to reduce the abnormal accumulation of alpha-synuclein protein in nerve cells derived from people with Parkinson’s disease, showing its potential for treating the neurodegenerative disorder, according to a new study. Metabolites are molecules that result from the biochemical…

Grant will advance VNA-318 for Parkinson’s, age-related diseases

The Swiss company Vandria has been awarded a multimillion-dollar research grant to help advance the development of VNA-318, its therapy candidate for age-related neurological conditions, including Parkinson’s disease. Totaling 2.5 million Swiss francs (about $2.8 million), the grant is funded by the Swiss Innovation Agency Innosuisse, which provides…

Long-term tai chi for Parkinson’s patients may improve cognition

Long-term practice of the Chinese martial art tai chi for Parkinson’s disease was shown to ease nonmotor symptoms among patients in a yearlong trial in China. Specifically, improved cognition was seen among people with the neurodegenerative disease after one year of the exercise program, according to study data. Conversely, at…

Parkinson’s clinical trial of iRegene’s NouvNeu001 doses 1st patient

The first patient has been dosed, and the observation period completed, in a clinical trial in China that’s testing iRegene Therapeutics’ NouvNeu001 cell therapy for moderate to advanced Parkinson’s disease. The Phase 1/2 clinical trial (NCT06167681) started in early January at Beijing Hospital, following a green light from the…

Vaxxinity, University of Florida join for work on Parkinson’s vaccine

Vaxxinity has entered into a research collaboration with the University of Florida to advance the development of vaccines for neurodegenerative diseases, including Parkinson’s disease. Funded by a grant from the state of Florida, the partnership aims to advance Vaxxinity’s lead immunotherapy candidates, designed to prevent and manage…

MJFF grant supports work into oral therapy to protect nerve cells

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded an $873,000 grant to Vesper Bio to advance the preclinical development of small-molecule therapies aiming to increase progranulin levels in people with Parkinson’s disease. Low levels of progranulin, a protein critical for immune activity and…

Brain imaging method may aid mild traumatic brain injury diagnosis

A new brain imaging method may help diagnose mild traumatic brain injury (mTBI), which according to some studies can be associated with a 50% higher risk of developing Parkinson’s. Available methods, like magnetic resonance imaging (MRI), leave most cases of mTBI, or concussions, undiagnosed. They occur when a physical…